Multidrug treatment using Kampo medicine for COVID-19 and other viral infections
Multidrug treatment for COVID-19 and other viral infections
DOI:
https://doi.org/10.51094/jxiv.2394キーワード:
COVID-19、 influenza、 Kampo medicine、 minocycline抄録
Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in late 2019 and has since become a major global threat to human health. New drugs such as remdesivir, and molnupiravir were developed. They are effective to some extent, but expensive. Besides such chemical compounds, many natural compounds have been tested by researchers for COVID-19 treatment. Consequently, natural active compounds providing antiviral and/or anti-inflammatory effects, have been found. Kampo medicines (i.e., Kakkon-to, Sho-saiko-to-ka-kikyosekko, and Saiko-keishi-to), that are mainly created using organic plant-based ingredients, have been prescribed during the COVID-19 pandemic. Regarding treatment using Kampo medicines for COVID-19, a combination of Kakkon-to and Sho-saiko-to-ka-kikyo-sekko was reportedly effective for fever, suppressing disease progression in patients with COVID-19. Similarly, a combination of Saiko-keishi-to and minocycline that has also anti-SARS-CoV-2 and anti-inflammatory effects, was reportedly effective for COVID-19 in acute and subacute phases. Aforementioned multidrug treatment is more effective than single-drug treatment because of the synergistic effects associated with the different mechanisms of action of the concerned drugs. Patients with influenza are also treated using Kampo medicines such as a combination of Mao-to and Sho-saiko-to in consideration of their anti-influenza effects. Recently, multidrug treatments using Kampo medicines for monkey-pox, severe fever with thrombocytopenia syndrome, and Crimean-Congo hemorrhagic fever have been proposed. Taken together, multidrug treatments using Kampo medicines may be effective against a variety of viral infections. In any case, clinical trials are warranted to better assess the optimal doses and durations, as well as the efficacy and tolerability, before these multidrug treatments can be recommended on a wider basis.
利益相反に関する開示
The authors have no conflicts of interest associated with this article.ダウンロード *前日までの集計結果を表示します
引用文献
Lv Y, Wang S, Liang P, Wang Y, Zhang X, Jia Q, et al. Screening and evaluation of anti-SARS-CoV-2 components from Ephedra sinica by ACE2/CMC-HPLC-IT-TOF-MS approach. Anal Bioanal Chem. 2021 May;413(11):2995-3004.
Fazil M, Nikhat S. Therapeutic and palliative role of a Unani herbal decoction in COVID-19 and similar respiratory viral illnesses: Phytochemical & pharmacological perspective. J Ethnopharmacol. 2022 Oct 28;297:115526.
Bahbah EI, Negida A, Nabet MS. Purposing Saikosaponins for the treatment of COVID-19. Med Hypotheses. 2020 Apr 23;140:109782.
Yuan B, Yang R, Ma Y, Zhou S, Zhang X, Liu Y. A systematic review of the active saikosaponins and extracts isolated from Radix Bupleuri and their applications. Pharm Biol. 2017;55:620-35.
Zheng W, Huang X, Lai Y, Liu X, Jiang Y, Zhan S. Glycyrrhizic acid for COVID-19: findings of targeting pivotal inflammatory pathways triggered by SARS-CoV-2. Front Pharmacol. 2021 Jun 9;12:631206.
Takayama S, Namiki T, Arita R, Ono R, Kikuchi A, Ohsawa M, et al. Multicenter, randomized controlled trial of traditional Japanese medicine, kakkonto with shosaikotokakikyosekko, for mild and moderate coronavirus disease patients. Front Pharmacol. 2022 Nov 9;13:1008946.
Ohe M, Furuya K, Goudarzi H. Tetracycline treatment for COVID-19. Gazi Med J. 2021;32:686-7.
Ohe M, Shida H, Yamamoto J, Seki M, Furuya K, Nishio S. COVID-19 Treated with Minocycline and Saiko-keishi-to: A Case Report. Intern Med J. 2024;31:27-8.
Ohe M, Shida H, Yamamoto J, Seki M, Furuya K. Successful treatment with minocycline and Saiko-keishi-to for COVID-19. J CLIN EXP INVEST. 2023;14(2): em00815. https://doi.org/10.29333/jcei/12999
Tsuchida N, Ohe M. Treatment with Kampo Medicine and Minocycline for Influenza. Intern Med J. 2025;32:162-3.
Yaegashi H. Efficacy of Coadministration of Maoto and Shosaikoto, a Japanese traditional herbal medicine (Kampo medicine), for the treatment of influenza A infection, in comparison to oseltamivir. Nihon Hokan Daitai Iryo Gakkaishi. 2010;7:59-62.
Ohe M. Drug Repurposing with Minocycline and Japanese Kampo Medicine for Mpox: Predicting Efficacy through In Silico Studies. Intern Med J. 2025;32:2-3.
Ohe M. Multidrug Treatment Using Kampo Medicine for Severe Fever with Thrombocytopenia Syndrome. Preprints 2025, 2025090637. https://doi.org/10.20944/preprints202509.0637.v1
Ohe M. Commentary: Combination Treatment Using Favipiravir for Crimean-Congo Hemorrhagic Fever. https://doi.org/10.51094/jxiv.1594
ダウンロード
公開済
投稿日時: 2025-12-24 11:36:01 UTC
公開日時: 2025-12-26 08:04:52 UTC
ライセンス
Copyright(c)2025
Ohe, Masashi
Ken Furuya
この作品は、Creative Commons Attribution-NonCommercial 4.0 International Licenseの下でライセンスされています。
